The incorporation of artificial intelligence (AI) across biomanufacturing and diagnostics is gaining strategic momentum. While regulators like the FDA and EMA explore adaptive frameworks to oversee AI-enabled manufacturing innovations, companies are deploying AI platforms to streamline clinical workflows and enhance diagnostic precision. Notably, Latent Health’s AI platform reduced prior authorization times dramatically, and Imagene AI raised $23 million to develop multimodal digital pathology models, signaling the rising role of AI in accelerating biopharma development and patient care.